Selpercatinib-话题@MedSci

#Selpercatinib#

10篇内容 | 1149人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2176200, encodeId=a37021e620019, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a> <a href='/topic/show?id=376e16120ab' target=_blank style='color:#2F92EE;'>#Selpercatinib#</a> <a href='/topic/show?id=90c21089425f' target=_blank style='color:#2F92EE;'>#铂类化疗#</a>, objectTitle=NEJM：Selpercatinib治疗晚期RET融合阳性NSCLC患者的无进展生存期明显更长, objectType=article, longId=806193, objectId=8c268061935d, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-in-his-practice-with-a-digital-tablet-UWZKVBN.jpg, objectUrl=/article/show_article.do?id=8c268061935d, replyNumber=0, likeNumber=44, createdTime=2023-12-20, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=8c268061935d, moduleTitle=NEJM：Selpercatinib治疗晚期RET融合阳性NSCLC患者的无进展生存期明显更长, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c268061935d)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2092807, encodeId=4379209280e77, content=<a href='/topic/show?id=f336e29134' target=_blank style='color:#2F92EE;'>#FDA#</a>批准的创新药物，如<a href='/topic/show?id=74ec10492098' target=_blank style='color:#2F92EE;'>#呋替巴替尼#</a>，<a href='/topic/show?id=a6f41049212a' target=_blank style='color:#2F92EE;'>#deucravacitinib#</a>，<a href='/topic/show?id=4b3d104922f2' target=_blank style='color:#2F92EE;'>#spesolimab#</a>，<a href='/topic/show?id=376e16120ab' target=_blank style='color:#2F92EE;'>#Selpercatinib#</a>，<a href='/topic/show?id=468410492308' target=_blank style='color:#2F92EE;'>#eflapegrastim#</a>等，<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>，皮肤风湿免疫仍然是大头。下部分应是<a href='/topic/show?id=5a8be955621' target=_blank style='color:#2F92EE;'>#罕见病#</a>一类, objectTitle=FDA在2022年第三季度批准了哪些创新药（上）？, objectType=article, longId=742664, objectId=ced9e4266497, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20221009/ab2e59afdf774f8881a31e168706d9f7.jpg, objectUrl=/article/show_article.do?id=ced9e4266497, replyNumber=0, likeNumber=90, createdTime=2022-10-10, rootId=0, userName=lifestar, userId=aa0e14, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ced9e4266497, moduleTitle=FDA在2022年第三季度批准了哪些创新药（上）？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ced9e4266497)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2090403, encodeId=554a2090403a0, content=<a href='/topic/show?id=f336e29134' target=_blank style='color:#2F92EE;'>#FDA#</a> 批准 <a href='/topic/show?id=376e16120ab' target=_blank style='color:#2F92EE;'>#Selpercatinib#</a> 用于<a href='/topic/show?id=5fa810485282' target=_blank style='color:#2F92EE;'>#不限癌种#</a>治疗携带<a href='/topic/show?id=528310485345' target=_blank style='color:#2F92EE;'>#RET基因#</a>融合的局部晚期或转移性<a href='/topic/show?id=13db460162d' target=_blank style='color:#2F92EE;'>#实体瘤#</a>患者。这是又一个不限癌种的治疗获批！！相信这是大趋势，未来依据靶点治疗，越来越不限癌种，这也给一些少见的瘤种带来治疗机会！, objectTitle=FDA 批准 Selpercatinib 用于不限癌种治疗携带RET基因融合的局部晚期或转移性实体瘤患者, objectType=article, longId=740891, objectId=21d7e4089159, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20220915/64b6637039744a618c9c190fa59ec28c.jpg, objectUrl=/article/show_article.do?id=21d7e4089159, replyNumber=0, likeNumber=125, createdTime=2022-09-26, rootId=0, userName=小小医者, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=21d7e4089159, moduleTitle=FDA 批准 Selpercatinib 用于不限癌种治疗携带RET基因融合的局部晚期或转移性实体瘤患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=21d7e4089159)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=2089218, encodeId=f7f22089218fd, content=<a href='/topic/show?id=376e16120ab' target=_blank style='color:#2F92EE;'>#Selpercatinib#</a>（也称为<a href='/topic/show?id=bfac104e9710' target=_blank style='color:#2F92EE;'>#LOXO-292#</a>）治疗<a href='/topic/show?id=a624104e98a8' target=_blank style='color:#2F92EE;'>#RET突变#</a>型<a href='/topic/show?id=f4d069924e7' target=_blank style='color:#2F92EE;'>#甲状腺髓样癌#</a>（MTC）的LIBRETTO-531临床试验（NCT04211337）已开始。这是第二项针对selpercatinib的III期临床试验。入组患者将被随机分配接受selpercatinib或医生选择的疗法。 , objectTitle=RET突变型甲状腺髓样癌：selpercatinib的III期临床试验已开始, objectType=article, longId=185522, objectId=448618552283, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/webeditor/uploadfile/201912/20191231164157354.jpeg, objectUrl=/article/show_article.do?id=448618552283, replyNumber=0, likeNumber=46, createdTime=2022-09-20, rootId=0, userName=小小医者, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=448618552283, moduleTitle=RET突变型甲状腺髓样癌：selpercatinib的III期临床试验已开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=448618552283)], followStatus=false, userIsMember=true, type=1, lengthMark=1), GetTopicListResponse(id=1460291, encodeId=ea101460291a2, content=<a href='/topic/show?id=376e16120ab' target=_blank style='color:#2F92EE;'>#Selpercatinib#</a>, objectTitle=Clin Cancer Res：Selpercatinib在已发生脑转移的RET融合阳性NSCLC患者中的疗效(LIBRETTO-001研究), objectType=article, longId=215428, objectId=756f215428da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=756f215428da, replyNumber=0, likeNumber=43, createdTime=2021-08-09, rootId=0, userName=Smile2682, userId=a8b36283029, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=756f215428da, moduleTitle=Clin Cancer Res：Selpercatinib在已发生脑转移的RET融合阳性NSCLC患者中的疗效(LIBRETTO-001研究), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=756f215428da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460290, encodeId=c24d1460290e8, content=<a href='/topic/show?id=376e16120ab' target=_blank style='color:#2F92EE;'>#Selpercatinib#</a>, objectTitle=NEJM：Selpercatinib用于RET融合阳性非小细胞肺癌患者的治疗, objectType=article, longId=199973, objectId=8ec51999e38c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ec51999e38c, replyNumber=0, likeNumber=41, createdTime=2020-08-29, rootId=0, userName=Smile2682, userId=a8b36283029, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ec51999e38c, moduleTitle=NEJM：Selpercatinib用于RET融合阳性非小细胞肺癌患者的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ec51999e38c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460289, encodeId=3541146028920, content=<a href='/topic/show?id=376e16120ab' target=_blank style='color:#2F92EE;'>#Selpercatinib#</a>, objectTitle=NEJM：Selpercatinib用于RET突变甲状腺髓样癌的治疗, objectType=article, longId=199972, objectId=ffdb1999e20f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ffdb1999e20f, replyNumber=0, likeNumber=0, createdTime=2020-08-29, rootId=0, userName=Smile2682, userId=a8b36283029, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ffdb1999e20f, moduleTitle=NEJM：Selpercatinib用于RET突变甲状腺髓样癌的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ffdb1999e20f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460288, encodeId=dcb8146028866, content=<a href='/topic/show?id=376e16120ab' target=_blank style='color:#2F92EE;'>#Selpercatinib#</a>, objectTitle=FDA：礼来口服RET抑制剂selpercatinib在美国上市, objectType=article, longId=193914, objectId=5fd0193914a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5fd0193914a4, replyNumber=0, likeNumber=46, createdTime=2020-05-12, rootId=0, userName=Smile2682, userId=a8b36283029, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5fd0193914a4, moduleTitle=FDA：礼来口服RET抑制剂selpercatinib在美国上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5fd0193914a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460287, encodeId=b075146028e87, content=<a href='/topic/show?id=376e16120ab' target=_blank style='color:#2F92EE;'>#Selpercatinib#</a>, objectTitle=非小细胞肺癌及甲状腺癌治疗传喜讯：Selpercatinib的新药申请获得优先审查, objectType=article, longId=187031, objectId=cbf718e0312f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cbf718e0312f, replyNumber=0, likeNumber=58, createdTime=2020-02-01, rootId=0, userName=Smile2682, userId=a8b36283029, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cbf718e0312f, moduleTitle=非小细胞肺癌及甲状腺癌治疗传喜讯：Selpercatinib的新药申请获得优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cbf718e0312f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460286, encodeId=34a81460286e3, content=<a href='/topic/show?id=376e16120ab' target=_blank style='color:#2F92EE;'>#Selpercatinib#</a>, objectTitle=RET突变型甲状腺髓样癌：selpercatinib的III期临床试验已开始, objectType=article, longId=185522, objectId=448618552283, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=448618552283, replyNumber=0, likeNumber=42, createdTime=2020-01-02, rootId=0, userName=Smile2682, userId=a8b36283029, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=448618552283, moduleTitle=RET突变型甲状腺髓样癌：selpercatinib的III期临床试验已开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=448618552283)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460285, encodeId=a049146028509, content=<a href='/topic/show?id=376e16120ab' target=_blank style='color:#2F92EE;'>#Selpercatinib#</a>, objectTitle=高明教授：RET高选择性抑制剂Selpercatinib(LOXO-292)给甲状腺癌患者带来新希望, objectType=article, longId=181524, objectId=3d71181524a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d71181524a9, replyNumber=0, likeNumber=38, createdTime=2019-10-20, rootId=0, userName=Smile2682, userId=a8b36283029, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d71181524a9, moduleTitle=高明教授：RET高选择性抑制剂Selpercatinib(LOXO-292)给甲状腺癌患者带来新希望, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d71181524a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Selpercatinib

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#非小细胞肺癌# #Selpercatinib# #铂类化疗#

NEJM：Selpercatinib治疗晚期RET融合阳性NSCLC患者的无进展生存期明显更长

2023-12-20发表于上海

lifestar (审核中...)

前往app查看评论内容

#FDA#批准的创新药物，如#呋替巴替尼#，#deucravacitinib#，#spesolimab#，#Selpercatinib#，#eflapegrastim#等，#肿瘤#，皮肤风湿免疫仍然是大头。下部分应是#罕见病#一类

FDA在2022年第三季度批准了哪些创新药（上）？

2022-10-10

(审核中...)

前往app查看评论内容

#FDA# 批准 #Selpercatinib# 用于#不限癌种#治疗携带#RET基因#融合的局部晚期或转移性#实体瘤#患者。这是又一个不限癌种的治疗获批！！相信这是大趋势，未来依据靶点治疗，越来越不限癌种，这也给一些少见的瘤种带来治疗机会！

FDA 批准 Selpercatinib 用于不限癌种治疗携带RET基因融合的局部晚期或转移性实体瘤患者

2022-09-26

(审核中...)

前往app查看评论内容

全文收起 #Selpercatinib#（也称为#LOXO-292#）治疗#RET突变#型#甲状腺髓样癌#（MTC）的LIBRETTO-531临床试验（NCT04211337）已开始。这是第二项针对selpercatinib的III期临床试验。入组患者将被随机分配接受selpercatinib或医生选择的疗法。

RET突变型甲状腺髓样癌：selpercatinib的III期临床试验已开始

2022-09-20

Smile2682 (审核中...)

前往app查看评论内容

#Selpercatinib#

Clin Cancer Res：Selpercatinib在已发生脑转移的RET融合阳性NSCLC患者中的疗效(LIBRETTO-001研究)

2021-08-09

Smile2682 (审核中...)

前往app查看评论内容

#Selpercatinib#

NEJM：Selpercatinib用于RET融合阳性非小细胞肺癌患者的治疗

2020-08-29

Smile2682 (审核中...)

前往app查看评论内容

#Selpercatinib#

NEJM：Selpercatinib用于RET突变甲状腺髓样癌的治疗

2020-08-29

Smile2682 (审核中...)

前往app查看评论内容

#Selpercatinib#

FDA：礼来口服RET抑制剂selpercatinib在美国上市

2020-05-12

Smile2682 (审核中...)

前往app查看评论内容

#Selpercatinib#

非小细胞肺癌及甲状腺癌治疗传喜讯：Selpercatinib的新药申请获得优先审查

2020-02-01

Smile2682 (审核中...)

前往app查看评论内容

#Selpercatinib#

RET突变型甲状腺髓样癌：selpercatinib的III期临床试验已开始

2020-01-02

Smile2682 (审核中...)

前往app查看评论内容

#Selpercatinib#

高明教授：RET高选择性抑制剂Selpercatinib(LOXO-292)给甲状腺癌患者带来新希望

2019-10-20

科室
- - 订阅+
  - 更多科室
工具
服务